<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400322</url>
  </required_header>
  <id_info>
    <org_study_id>MV20145</org_study_id>
    <secondary_id>2006-002022-29</secondary_id>
    <nct_id>NCT00400322</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection</brief_title>
  <official_title>A Randomized Double Blind Controlled Proof of Concept Study of the Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma With Successful Surgical Resection of at Least 90 % of the Initial Tumor and CMV Infection Demonstrated Histologically and Immunohistochemically.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if treatment of CMV infection by antiviral drug&#xD;
      Valcyte (R) affects the clinical outcome of glioblastoma multiforme in patients with local&#xD;
      CMV infection in tumor tissue. The investigators' hypothesis states that CMV infection&#xD;
      promotes tumor development and disease progression and inhibits immune responses against the&#xD;
      tumor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor size</measure>
    <time_frame>Week twelve</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor size</measure>
    <time_frame>Week twenty four</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease status</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Cytomegalovirus Infection</condition>
  <arm_group>
    <arm_group_label>Valganciclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir (Valcyte)</intervention_name>
    <arm_group_label>Valganciclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Glioblastoma grade IV&#xD;
&#xD;
          -  Cytomegalovirus detected in tumor&#xD;
&#xD;
          -  At least 90% resection of tumor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Decreased kidney function&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Neutropenia&#xD;
&#xD;
          -  Thrombocytopenia&#xD;
&#xD;
          -  Patient not tolerating the drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inti Peredo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cecilia Soderberg-Naucler, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of neurosurgery, Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <state>Stockholm</state>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Norrland University Hospital</name>
      <address>
        <city>Umea</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Akademiska Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 15, 2006</study_first_submitted>
  <study_first_submitted_qc>November 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2006</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Cecilia Soderberg-Naucler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>glioblastoma multiforme</keyword>
  <keyword>cytomegalovirus infection</keyword>
  <keyword>antiviral treatment</keyword>
  <keyword>valganciclovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

